➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Dow
McKinsey
Colorcon
Johnson and Johnson

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,592,434

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,592,434 protect, and when does it expire?

Patent 8,592,434 protects SITAVIG and is included in one NDA.

This patent has fourteen patent family members in thirteen countries.

Summary for Patent: 8,592,434
Title:Mucoadhesive buccal tablets for the treatment of orofacial herpes
Abstract: The present invention relates to the treatment or prevention of mucocutaneous herpes simplex virus diseases using prolonged release mucoadhesive buccal tablets comprising an acyclic guanosine antiviral agent. These tablets are particularly suitable for the treatment or prevention of orofacial herpes.
Inventor(s): Attali; Pierre (Vincennes, FR), Costantini; Dominique (Paris, FR), Lemarchand; Caroline (Paris, FR)
Assignee: BioAlliance Pharma SA (Paris, FR)
Application Number:12/634,225
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,592,434

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Epi Hlth SITAVIG acyclovir TABLET;BUCCAL 203791-001 Apr 12, 2013 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF HERPES LABIALIS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,592,434

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2782779   Start Trial
China 102652016   Start Trial
Denmark 2509586   Start Trial
European Patent Office 2335690   Start Trial
European Patent Office 2509586   Start Trial
Spain 2678122   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Moodys
Express Scripts
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.